{
    "thread": {
        "uuid": "dde48c50d37c2bbeb84ae45478559877349e457b",
        "url": "http://3g.cnfol.com/sc_stock/ggzixun/20250424/31266493.shtml",
        "site_full": "3g.cnfol.com",
        "site": "cnfol.com",
        "site_section": "https://3g.cnfol.com/sc_stock/ggzixun",
        "site_categories": [],
        "section_title": "个股资讯_市场_中金在线\t\t",
        "site_title": null,
        "title": "荃信生物-B(02509)与Caldera Therapeutics就QX030N的开发及商业化订立独家授权协议_手机中金在线",
        "title_full": "荃信生物-B(02509)与Caldera Therapeutics就QX030N的开发及商业化订立独家授权协议_手机中金在线",
        "published": "2025-04-24T02:28:13.784+03:00",
        "replies_count": 0,
        "participants_count": 0,
        "site_type": "news",
        "country": "CN",
        "main_image": "",
        "performance_score": 0,
        "domain_rank": 10601,
        "domain_rank_updated": "2025-04-22T00:00:00.000+03:00",
        "licensing_agency": [],
        "social": {
            "facebook": {
                "likes": 0,
                "comments": 0,
                "shares": 0
            },
            "vk": {
                "shares": 0
            }
        }
    },
    "uuid": "dde48c50d37c2bbeb84ae45478559877349e457b",
    "url": "http://3g.cnfol.com/sc_stock/ggzixun/20250424/31266493.shtml",
    "ord_in_thread": 0,
    "author": null,
    "published": "2025-04-24T02:28:13.784+03:00",
    "title": "荃信生物-B(02509)与Caldera Therapeutics就QX030N的开发及商业化订立独家授权协议_手机中金在线",
    "text": "荃信生物-B(02509)与Caldera Therapeutics就QX030N的开发及商业化订立独家授权协议\n智通财经\n|智通财经APP讯，荃信生物-B(02509)发布公告，于2025年4月23日，公司与Caldera Therapeutics订立一项对外授权协议(授权协议)。授权协议授予Caldera Therapeutics开发及商业化QX030N的全球独家许可。\n根据授权协议的条款及条件，Caldera Therapeutics获授独家、须支付特许权使用费、可转让、可再授权的权利，以在全球范围内研究、开发、注册、生产及商业化 QX030N。作为回报，公司或其指定联属公司(统称“集团”)将有权获得一次性、不可退还及不可抵扣的预付款1000万美元，以及获得Caldera Therapeutics约24.88%的股权。在达成特定临床开发、监管及商业里程碑的前提下，集团亦可获得最高5.45亿美元的额外付款。在QX030N首次商业销售后的一段特定时间内，集团亦将有权从Caldera Therapeutics的销售净额中收取分级特许权使用费。\n就授权协议而言，公司与Caldera Therapeutics亦已于授权协议的同一日订立股份收购协议，集团同意收购Caldera Therapeutics的上述股权。\n董事会相信，订立授权协议将非常有助于公司在生物医药领域的业务拓展，并符合公司及股东的整体最佳利益。公司将继续透过其创新技术平台进一步加强全球合作网络，从而最大化集团的管线价值及商业价值。\n【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱：news_center@staff.hexun.com\n加载全文",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "chinese",
    "sentiment": "positive",
    "categories": [
        "Health",
        "Economy, Business and Finance",
        "Social Issue"
    ],
    "topics": [
        "Health->medical service",
        "Health->health organisation",
        "Economy, Business and Finance->business governance",
        "Economy, Business and Finance->healthcare industry",
        "Social Issue->social networking",
        "Social Issue->demographics",
        "Social Issue->social condition"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": false,
    "webz_reporter": false,
    "external_links": [],
    "entities": {
        "persons": [],
        "locations": [],
        "organizations": []
    },
    "syndication": {
        "syndicated": null,
        "syndicate_id": null,
        "first_syndicated": false
    },
    "trust": {
        "categories": [],
        "bias": null,
        "source": {
            "type": null,
            "city": null,
            "state": null,
            "country": null,
            "domain_type": null,
            "agency": null,
            "organization_name": null
        }
    },
    "rating": null,
    "crawled": "2025-04-24T02:28:13.784+03:00",
    "updated": "2025-04-24T02:28:13.784+03:00"
}